Blade Air Mobility: Disappointing Exit

Blade Air Mobility (BLDE) has sold its Urban Air Mobility (UAM) passenger division to Joby Aviation (JOBY) for up to $125 million, rebranding as Strata Critical Medical to exclusively focus on its medical services segment. While this strategic shift enhances Blade's capital position and creates a financially sound, albeit lower-growth, medical logistics entity, it divests the company from its original, high-potential UAM strategy. The market's strong positive reaction to Joby, whose stock surged 19% post-announcement, suggests the deal was highly advantageous for Joby, implying Blade may have sold its UAM assets at a significant discount.

Analysis

Blade Air Mobility (BLDE) has executed a significant strategic pivot, divesting its passenger division to Joby Aviation (JOBY) in a deal valued at up to $125 million, with $90 million guaranteed. This transaction effectively removes Blade from the high-growth Urban Air Mobility (UAM) sector, which was its original investment thesis, in favor of rebranding as Strata Critical Medical and focusing exclusively on its organ transplant logistics business. The sold division generated $105 million in TTM revenues, implying a sale multiple of less than 1x sales. The market's reaction, a 19% surge in JOBY's stock corresponding to a $2.75 billion market cap increase, strongly suggests that Blade's UAM assets were sold at a substantial discount. The remaining entity, Strata, is a formidable player in its niche, targeting ~$150 million in 2025 revenue with an existing 30% share of the $1 billion organ logistics market. Post-transaction, Blade's valuation appears compelling on a fundamental basis, with a market cap of $365 million and a pro-forma enterprise value of approximately $100 million. With projected cost savings of $7 million and a 2024 adjusted EBITDA base of $19 million, the new entity could achieve an adjusted EBITDA of around $25 million, resulting in a forward EV/EBITDA multiple of just 4x. While the deal establishes a financially stable and profitable company, it caps the exponential upside previously associated with the UAM narrative.

Key Decisions for Investors

• Investors who held Blade for its high-growth Urban Air Mobility thesis should re-evaluate their position, as the company has fundamentally pivoted to a more stable, lower-upside medical logistics model.
• The new entity, Strata, presents a potential opportunity for value-focused investors, given its low forward enterprise value to adjusted EBITDA multiple of approximately 4x and its dominant market share in organ logistics.
• Monitor the company's ability to achieve its projected $25 million in adjusted EBITDA and defend its 30% market share, as performance in the more constrained medical services market is now the primary driver of shareholder value.
• The deal significantly de-risks Joby Aviation's go-to-market strategy by providing it with an established infrastructure and passenger base, making JOBY a more direct, albeit more richly valued, investment in the future of UAM.